Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:23:21 EDT Fri 17 May 2024
Enter Symbol
or Name
USA
CA



Q:OCUP - OCUPHIRE PHARMA INC - https://www.ocuphire.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OCUP - Q0.11.67·1.950.11.735    4.9968  1.50May 16May 1015 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-10 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
2024-05-06 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
2024-05-03 08:00U:OCUPNews ReleaseOcuphire Pharma to Present at the Aegis Virtual Conference
2024-04-22 08:00U:OCUPNews ReleaseOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
2024-04-11 10:04U:OCUPNews ReleaseFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
2024-04-01 07:15U:OCUPNews ReleaseOcuphire Announces the U.S. Commercial Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
2024-03-08 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
2024-02-23 08:00U:OCUPNews ReleaseOcuphire Pharma to Present in the BIO CEO & Investor Conference
2024-02-15 16:10U:OCUPNews ReleaseOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-14 08:00U:OCUPNews ReleaseOcuphire Pharma Strengthens Leadership Team with Key Appointments
2024-02-05 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
2024-01-24 16:10U:OCUPNews ReleaseOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 08:00U:OCUPNews ReleaseOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
2023-11-30 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
2023-11-27 16:38U:OCUPNews ReleaseOcuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
2023-11-13 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
2023-11-02 08:00U:OCUPNews ReleaseOcuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
2023-11-01 16:53U:OCUPNews ReleaseOcuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-01 08:05U:OCUPNews ReleaseOcuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director